Compare Cytokinetics Inc (CYTK) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62.15 (market cap $78.85B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 7.4× Cytokinetics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.24% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MDLZ | |
|---|---|---|
Market Cap | $10.63B | $78.85B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $64.99 |
52-Week Low | $34.31 | $51.51 |
Enterprise Value | $10.74B | $99.19B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
MDLZ trades at $61.99, up 0.75% today, with a bullish technical signal from moving averages and support at $61. The company reported Q2 2026 EPS of $0.73, beating estimates, and raised its organic sales outlook. Revenue grew to $38.54B in 2025, though net income margin declined to 6.36%. Analyst consensus is strongly bullish with a $70.50 price target.
Outlook is positive due to earnings beats and emerging market growth, but risks include margin pressure and high P/E of 37.75. Institutional activity is mixed, with some firms increasing stakes while others reduced holdings. The stock offers upside to target but faces execution risks in a competitive consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
